Dr. Annalisa Jenkins
Acting Non-Executive Chair
Annalisa has a degree in Medicine from St. Bartholomew’s Hospital, served as a medical officer in the British Navy and was a specialist registrar in Cardiovascular Medicine with UK NHS.
Dr. Annalisa Jenkins has approximately 25 years of experience in building and leading teams that advanced programmes from scientific research through clinical development, regulatory approval and into healthcare systems globally. Until 2017, she was Chief Executive Officer of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Prior to this, Annalisa served as executive vice president, Head of Global Research and Development, at Merck Serono where she also led global medical affairs and quality. She also held several roles of increasing responsibility at Bristol Myers-Squibb, culminating as Senior Vice President and Head of Global Affairs.
Annalisa has a degree in Medicine from St. Bartholomew’s Hospital, served as a medical officer in the British Navy and was a specialist registrar in Cardiovascular Medicine with UK NHS. She currently chairs the boards of Cell Medica, Vium, Silence Therapeutics and Cocoon Biotech, and is a director on the boards of Oncimmune, Compass Pathways, Avrobio, AOBiome, PhESi, Thrombolytic Science, Ardelyx, iOx Therapeutics and MedCity. In addition, she is a committee member of the Science Board to the FDA, and the Chair of the Court at the London School of Hygiene and Tropical Medicine.